Finasteride can be used to treat patients with prostate enlargement by lowering their serum PSA levels. PSA, short for Prostatic Specific Antigen, is an important serum indicator of prostate disease and has implications for the treatment of androgenetic alopecia. Serum PSA concentrations correlate with patient age and prostate volume, which in turn correlates with patient age. It has been found that in the treatment of prostate patients, PSA decreases rapidly during the first month of treatment and then PSA levels remain stable. Patients treated with finasteride tablets for more than 6 months have reduced PSA values when compared to normal serum prostate-specific antigen (PSA) values in patients not treated with finasteride tablets. In addition, in the treatment of androgenetic alopecia, a clinical study in men between the ages of 18 and 41 years noted a reduction in serum prostate-specific antigen (PSA) of approximately 50% from a basal level of 0.7 ng/ml after 12 months of finasteride use. The use of the drug may cause adverse reactions such as loss of libido and impotence, and it is contraindicated for people who are allergic to the product, women and other people. The drug should be applied under medical supervision.